後藤　励 （ ゴトウ　レイ ）

Goto, Rei

写真a

所属（所属キャンパス）

経営管理研究科 （ 日吉 ）

職名

教授
Scopus 論文情報  
総論文数: 102 総引用数: 1171 h-index: 20

Click to view the Scopus page. The data was downloaded from Scopus API inJuly 19, 2026, via http://api.elsevier.com and http://www.scopus.com .

このページの先頭へ▲

その他の所属・職名 【 表示 ／ 非表示 】

  • 健康マネジメント研究科

このページの先頭へ▲

経歴 【 表示 ／ 非表示 】

  • 1998年05月
    -
    2000年03月

    神戸市立中央市民病院, 臨床研修医（内科）

  • 2005年04月
    -
    2007年03月

    甲南大学, 経済学部, 専任講師

  • 2007年04月
    -
    2012年03月

    甲南大学, 経済学部, 准教授

  • 2012年04月
    -
    2016年03月

    京都大学, 白眉センター, 准教授

このページの先頭へ▲

学歴 【 表示 ／ 非表示 】

  • 1992年04月
    -
    1998年03月

    京都大学, 医学部

    大学, 卒業, その他

  • 2000年04月
    -
    2005年03月

    京都大学, 経済学研究科

    大学院, 修了, 博士

このページの先頭へ▲

学位 【 表示 ／ 非表示 】

  • 学士（医学）, 京都大学, 課程, 1998年03月

  • 博士（経済学）, 京都大学, 課程, 2006年05月

このページの先頭へ▲

免許・資格 【 表示 ／ 非表示 】

  • 医師, 1998年04月

このページの先頭へ▲
 

研究分野 【 表示 ／ 非表示 】

  • 人文・社会 / 経済政策

  • 人文・社会 / 公共経済、労働経済

  • ライフサイエンス / 医療管理学、医療系社会学

このページの先頭へ▲

研究キーワード 【 表示 ／ 非表示 】

  • 医療技術評価

  • 医療政策

  • 医療経済学

  • 行動経済学

このページの先頭へ▲
 

著書 【 表示 ／ 非表示 】

  • 健康経済学 -- 市場と規制のあいだで

    後藤励, 井深陽子, 有斐閣, 2020年03月

  • 医療レジリエンス　－医学アカデミアの社会的責任－

    福原俊一,後藤 励,中山健夫,川上浩司,福間真悟, 医学書院, 2015年

  • 日本のお医者さん研究

    森剛志,後藤 励, 東洋経済新報社, 2012年

  • 医療経済学講義

    後藤 励橋本英樹・泉田信行, 東京大学出版会, 2011年

    担当範囲: 第１０章　生活習慣と行動変容

  • 健康行動経済学

    依田高典,後藤 励,西村周三, 日本評論社, 2009年

全件表示 >>

このページの先頭へ▲

論文 【 表示 ／ 非表示 】

  • Organization-level factors associated with the adoption of care robots in long-term care providers: insights from a 3-year pooled cross-sectional study in Japan

    Tosaka Y., Funada S., Goto R.

    BMC Health Services Research 26 （ 1 ）  2026年12月

    　概要を見る

    Background: Care robots are expected to be useful in long-term care (LTC) settings to resolve several challenges associated with aging populations. However, their use is still limited and little is known about the factors associated with their adoption. This study aimed to identify the factors associated with the adoption of care robots, using a quantitative analysis of a large sample at the organizational level in Japan. Methods: We analyzed residential service providers using 3 years of pooled cross-sectional data from the Fact-Finding Survey on Long-term Care Work in Japan. In this survey, care robots were categorized as robots for “Transfer support,” “Mobility assistance,” “Toiletry support,” “Monitoring and Communication,” “Bathing support,” and “Support for LTC workers.” We defined “adoption of care robots” as LTC providers having adopted at least one of the care robots. To identify the characteristics of LTC providers associated with the adoption of care robots, we conducted a multivariable logistic regression comparing providers with and without care robots. Results: Of the 4,688 LTC providers, 1,250 (26.7%) adopted care robots. The characteristics of LTC providers that were found to be associated with the adoption of care robots were: information and communication technology (ICT) equipment adoption (adjusted odds ratio [aOR] 3.115, 95% confidence interval [CI] 2.453, 3.956), younger average age of care workers (aOR 0.958, 95% CI 0.945, 0.971), large number of employees (aOR 1.008, 95% CI 1.006, 1.010) and appointment of employment management supervisor (aOR 1.611, 95% CI 1.400, 1.853). The primary results were consistent across robot categories. Conclusions: Our findings suggest that care robot adoption is highly compatible with ICT equipment adoption, particularly among younger workers, and among large-scale providers and those with a high awareness of improving employment management indicated by the appointment of an employment management supervisor. To promote adoption, we suggest staff technology-literacy training (especially for senior employees), targeted financial incentives for small providers, and management-led integration of robots within employment-management improvements. This study identified the factors associated with the adoption of care robots at the organizational level and is expected to contribute to realizing the implementation of care robots.

  • Socioeconomic and financial factors associated with financial toxicity in Japanese cancer patients: a cross-sectional study

    Yokoyama K., Honda K., Matsumoto K., Ando Y., Ito M., Goto R., Shinno Y., Shimoi T., Suzuki T., Yoshioka T., Ishiki H.

    Japanese Journal of Clinical Oncology 56 （ 6 ） 731 - 740 2026年06月

    ISSN  03682811

    　概要を見る

    Background: Financial toxicity (FT) arises from the economic burden of cancer treatment and is associated with reduced quality of life and worse survival. However, its association with socioeconomic and financial factors among Japanese cancer patients has not been fully elucidated. Methods: Between October 2023 and May 2024, a cross-sectional study was conducted among adult cancer patients undergoing chemotherapy for at least two months at two cancer centers in Japan. Patients receiving public assistance or who had participated in clinical trials were excluded. FT was assessed using the Comprehensive Score for Financial Toxicity (COST). Lower COST scores indicate higher FT. Associations between COST score and clinical, demographic, socioeconomic, and financial factors were analyzed using univariable linear regression. Results: Of 258 patients invited, 245 responded, and 203 (78.7%) were analyzed. The median age was 62 years, and the most common primary tumor sites were head and neck (22.7%), colorectal (12.3%), and lung (11.3%). The median COST score was 22 (range: 2–41), with FT (COST <26) observed in 69.0% of patients. The use of coping strategies (β: −3.09; P = .03) and having debts or loans (β: −3.23; P = .04) were significantly associated with lower COST scores. Higher education (β: 3.61; P = .02), household annual income ≥14 million JPY (β: 8.44; P = .02), and savings of 10–12 million JPY (β: 9.99; P = .003) were associated with higher COST scores. Conclusion: In this study, 69.0% of Japanese cancer patients experienced FT. The identified socioeconomic and financial factors may help clinicians detect patients at risk of financial vulnerability.

  • Efficacy and Safety of a Telemedicine System in Patients With Gestational Diabetes Mellitus (TELEGLAM): Single-Center, 2-Arm, Randomized, Open-Label, Parallel-Group Study

    Aoyama K., Nakajima Y., Meguro S., Sato Y., Goto R., Hida M., Arimitsu T., Kasuga Y., Tanaka M., Itoh H., Hayashi K.

    Jmir Mhealth and Uhealth 14 2026年05月

    　概要を見る

    Background: In the management of gestational diabetes mellitus (GDM), the usual medical treatment requires frequent visits for glucose monitoring and insulin dose adjustment, and this imposes significant physical, psychological, and economic burdens on pregnant women. As mobile health platforms become increasingly integrated into diabetes care, telemedicine may help alleviate these burdens; however, evidence evaluating its effectiveness as a replacement for routine in-person GDM care remains limited. Objective: This study aims to evaluate the impact of telemedicine on the quality of life and costs for patients with GDM requiring insulin therapy. Methods: This single-center, 2-arm, randomized, open-label, parallel-group study included patients with GDM who started insulin injection therapy. Participants were randomized to either the telemedicine or standard face-to-face care groups for 10 (SD 2) weeks. The telemedicine intervention used a smartphone-linked platform that enabled the automatic transfer of glucose data from connected glucose meters and facilitated real-time video consultations. Primary end points included costs and patient satisfaction. Costs were assessed using claims data, transportation calculations, and wage-based productivity losses, while patient satisfaction was evaluated through changes in the Problem Areas in Diabetes Survey and Diabetes Therapy-Related Quality of Life questionnaire scores. Secondary outcomes included glycemic control and perinatal outcomes. Results: In total, 38 participants were included, with 18 assigned to the telemedicine group and 20 to the standard care group. Total costs (32,712, 95% CI 15,412-50,013 vs 59,202, 95% CI 42,603-75,800 Japanese yen; $284, 95% CI 134-435 vs $515, 95% CI 370-659, purchasing power parity [PPP]-adjusted; P=.01), direct non-health care costs (922, 95% CI -240 to 2084 vs 2561, 95% CI 1447-3676 yen; $8, 95% CI -2 to 18 vs $22, 95% CI 13 to 32 PPP-adjusted; P=.02), and indirect costs (8981, 95% CI -7119 to 25,082 vs 32,832, 95% CI 17,384-48,279 yen; $78, 95% CI -62 to 218 vs $285, 95% CI 151-420 PPP-adjusted; P=.01) reduced significantly in the telemedicine group compared with the standard care group. The improvements in the Problem Areas in Diabetes Survey (-7.6, 95% CI -13.7 to -1.4; P=.02) and Diabetes Therapy-Related Quality of Life domain 1 (10.5, 95% CI 0.9-20.1; P=.03) scores from the baseline were significantly greater in the telemedicine group than that in the standard care group. Nonetheless, glycemic control and frequency of perinatal complications were comparable between the 2 groups. Consultation time was similar across groups, suggesting no added workload for clinicians. Conclusions: In this randomized trial, mobile health-enabled telemedicine safely replaced routine in-person visits for patients with GDM requiring insulin therapy. Telemedicine significantly reduced psychological and economic burdens without compromising glycemic or perinatal outcomes, demonstrating its value as a patient-centered and cost-efficient model of care. These findings support the broader implementation of mobile-based telemedicine approaches in GDM management.

  • Determinants of polydoctoring among patients with multimorbidity: a Nationwide Longitudinal Fixed-Effects Study in Japan

    Ando T., Jani B.D., Haruta J., Goto R.

    Family Medicine and Community Health 14 （ 2 ）  2026年04月

    ISSN  23056983

    　概要を見る

    Objective: To identify which chronic conditions and patient characteristics contribute to increases in the number of regularly visited facilities (RVF), a measure of polydoctoring, among adults with multimorbidity in Japan. Design: Retrospective cohort study using individual fixed-effects Poisson regression models to estimate within-person associations between the onset of each chronic condition and changes in RVF. This approach controlled for all time-invariant personal characteristics. Effect modification by age, geographic region and baseline multimorbidity was also assessed. Setting: A nationwide health claims database covering multiple insurance systems in Japan, including municipal National Health Insurance, Employees’ Health Insurance and the Long-Life Medical Care System. Participants: 4 696 790 adults with two or more chronic conditions and two or more consecutive years of follow-up. Results: The onset of examined chronic conditions was associated with changes in RVF, with substantial variation in effect size across conditions. The strongest association was observed for malignancy (RR=1.102; 95% CI 1.101 to 1.103), followed by osteoporosis (RR=1.065; 95% CI 1.064 to 1.065), arthritis (RR=1.061; 95% CI 1.060 to 1.061), obesity (RR=1.049; 95% CI 1.044 to 1.055), stroke (RR=1.044; 95% CI 1.041 to 1.048) and cardiovascular disease (RR=1.043; 95% CI 1.042 to 1.044). Associations between disease onset and RVF were consistently attenuated among individuals aged ≥75 years and those with higher baseline multimorbidity while differences between urban and rural residents were minimal. Conclusion: Substantial heterogeneity was observed in the magnitude of RVF increases across chronic conditions, with particularly strong associations for malignancy, osteoporosis and arthritis. Attenuated effects among older adults and individuals with higher multimorbidity suggest that patient capacity and treatment burden may influence patterns of healthcare utilisation. These findings underscore condition-specific drivers of care fragmentation and may inform more tailored care-coordination strategies for people living with multimorbidity.

  • 連載 医療にいかす行動経済学・Vol.3 行動経済学とヘルスケア

    後藤 励

    医学のあゆみ （医歯薬出版）  296 （ 4 ） 319 - 324 2026年01月

    ISSN  00392359

全件表示 >>

このページの先頭へ▲

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

このページの先頭へ▲

総説・解説等 【 表示 ／ 非表示 】

  • Publisher Correction: The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025) (Hypertension Research, (2026), 49, 1, (9-235), 10.1038/s41440-025-02462-y)

    Ohya Y., Arakawa K., Arata N., Arima S., Arima H., Asayama K., Dohi Y., Fukami A., Furuhashi M., Goto K., Goto R., Hatta T., Hirawa N., Hirooka Y., Hisamatsu T., Hoshide S., Ikezumi Y., Inoue S., Ishida M., Ishimitsu T., Iwashima Y., Kabayama M., Kabutoya T., Kai H., Kaneko H., Kanno Y., Katsuya T., Kikuchi T., Koga M., Kudo M., Kuwabara M., Matsumura K., Metoki H., Mito A., Miura S.I., Miura K., Miyashita K., Mogi M., Kawakami-Mori F., Morimoto S., Mukai M., Mukoyama M., Munakata M., Nakagawa N., Ohkubo T., Okura T., Rakugi H., Shibata S., Shinohara K., Takami T., Takase H., Takemi Y., Tanaka A., Tomiyama H., Toyoda K., Tsuchihashi T., Ueda S., Yamamoto E., Yamamoto K., Sakima A.

    Hypertension Research 49 （ 4 ）  2026年04月

    ISSN  09169636

    　概要を見る

    Correction to: Hypertension Research https://doi.org/10.1038/s41440-025-02462-y, published online 01 January 2026 In the original version of this article, the author list was incorrectly located in the article body. The original article has been corrected.

  • Cost-effectiveness comparison between blood biomarkers and conventional tests in Alzheimer's disease diagnosis

    Noda K., Lim Y., Goto R., Sengoku S., Kodama K.

    Drug Discovery Today （Drug Discovery Today）  29 （ 3 ）  2024年03月

    ISSN  13596446

    　概要を見る

    Dementia management has evolved with drugs such as lecanemab, shifting management from palliative care to early diagnosis and intervention. However, the administration of these drugs presents challenges owing to the invasiveness, high cost and limited availability of amyloid-PET and cerebrospinal fluid tests for guiding drug administration. Our manuscript explores the potential of less invasive blood biomarkers as a diagnostic method, with a cost-effectiveness analysis and a comparison with traditional tests. Our findings suggest that blood biomarkers are a cost-effective alternative, but with lower accuracy, indicating the need for multiple specific biomarkers for precision. This underscores the importance of future research on new blood biomarkers and their clinical efficacy.

  • Re: Letter to the Editor of Public Health in response to ‘Effect of influenza vaccine subsidies for older adults on vaccination coverage and mortality before and during the COVID-19 pandemic: An ecological study in Japan’

    Ando T., Ibuka Y., Goto R., Haruta J., Le D.D., Fujishima S.

    Public Health （Public Health）  227   e3 - e4 2024年02月

    ISSN  00333506

  • 医療経済評価における小児のQOL値測定法とその課題

    本多 貴実子, 白岩 健, 後藤 励, 福田 敬

    保健医療科学 （国立保健医療科学院）  71 （ 3 ） 264 - 275 2022年08月

    ISSN  1347-6459

    　概要を見る

    適正な医療資源の配分のためのエビデンスを提供することを目的として行われる医療経済評価では,異なった領域の介入の比較を容易にするため,アウトカム指標を質調整生存年(Quality-adjusted life year:QALY)とすることが原則とされている.QALYは生存期間にQOL(Quality of life)を0から1の値に換算したQOL値を重み付けして得られる.QALYにはその国の人々の選好による重みづけが反映されることが望ましいという観点から,QOL値は国内の調査結果を優先的に使用することが推奨されているが,以前から日本人のデータが乏しいことが指摘されていた.近年成人ではその蓄積が進みつつあるが,小児においてはその測定に多くの課題があり,日本ではほぼ行われていないのが現状である.医療経済評価でQOL値測定に用いられる尺度は選好に基づく尺度(Preference-based measure:PBM)である.PBMによってQOL値を得る過程は,評価したい健康状態の「測定」と「価値づけ」に分けられる.これを一度に行うものを直接法,別々に行うものを間接法と呼ぶ.直接法には評点尺度法,時間得失法,基準的賭け法があるが,小児では実施可能性,信頼性,妥当性はまだ十分に検討されていない.成人も含め一般的に現在主流となっている間接法では,multi attribute utility instruments(MAUIs)と呼ばれる尺度を用い,実際にその健康状態にある人(患者)に自らの健康について質問票に記入してもらった後,換算表を用いてQOL値を算出する.一般的に成人を対象に開発されたMAUIsは,小児で使用するにあたって質問の記述の仕方や内容が適していない,さらに換算表が成人の健康についての価値付けになっているなどの問題があり,小児には小児用のMAUIsの使用が望ましいとされる.近年小児用のMAUIsの開発が進んできたが,各国での翻訳や換算表の有無により,どの国でもこれらが使用できるわけではなく,3歳以下の年少児では使用できるものは現在ない.また,どの領域をどのように評価するべきか,誰が記入するべきかなどの「測定」に関する課題,換算表の作成にあたって誰の選好をどの視点を使用して明らかにし,反映するべきなのかという「価値付け」の課題があり,現在あるMAUIsが十分に小児の健康関連QOLをとらえられていない可能性もある.日本ではこれまで小児の使用を想定したMAUIsがなかったが,最近EuroQol 5-dimension Youth version(EQ-5D-Y)日本語版とその換算表が発表され,今後日本人小児のデータの蓄積が期待される.小児のQOL値の測定と解釈にあたっては,その課題や限界を十分に理解しておく必要がある.(著者抄録)

  • 【すぐそこまで来た,医師の働き方改革-課題と実現可能性】医師の働き方改革とお金の問題

    後藤 励

    病院 （(株)医学書院）  81 （ 2 ） 127 - 129 2022年02月

    ISSN  0385-2377

全件表示 >>

このページの先頭へ▲

競争的研究費の研究課題 【 表示 ／ 非表示 】

  • 医療政策評価研究のためのレセプトデータ利用に関する基盤整備

    2015年04月
    -
    2018年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 後藤　励, 基盤研究(C), 補助金,  研究代表者

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 健康マネジメント概論

    2026年度

  • 健康行動科学

    2026年度

  • 健康マネジメント合同演習

    2026年度

  • ヘルスエコノミクス

    2026年度

  • 健康マネジメント特論Ⅱ

    2026年度

全件表示 >>

このページの先頭へ▲